scholarly journals Autologous Bone Marrow Aspirate Therapy for Skin Tissue Engineering and Tissue Regeneration

2017 ◽  
Vol 6 (4) ◽  
pp. 135-142 ◽  
Author(s):  
Gopal Ji Gupta ◽  
Kanchan Karki ◽  
Pradeep Jain ◽  
Ajit Kumar Saxena
Keyword(s):  
Tissue Engineering ◽  
Bone Marrow ◽  
Tissue Regeneration ◽  
Bone Marrow Aspirate ◽  
Autologous Bone Marrow ◽  
Skin Tissue ◽  
Skin Tissue Engineering ◽  
Autologous Bone

scholarly journals Autologous bone marrow aspirate concentrate (BMAC) for treatment of keratocystic odontogenic tumour (KCOT) —a case report

2021 ◽  
Vol 0 ◽  
pp. 0-0
Author(s):  
Manimaran Kanakaraj ◽  
Sangeetha Manoharan ◽  
Sivashankaran Srinivas ◽  
Marudhamani Chinnannan ◽  
Avinash Gandhi Devadas ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Case Report ◽  
Bone Marrow Aspirate ◽  
Autologous Bone Marrow ◽  
Odontogenic Tumour ◽  
Bone Marrow Aspirate Concentrate ◽  
Autologous Bone ◽  
Keratocystic Odontogenic Tumour

Intraarterial Versus Intramuscular Delivery of Autologous Bone Marrow Blood to Patients with Critical Limb Ischemia

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 2999-2999
Author(s):  
Martin Mistrik ◽  
Juraj Madaric ◽  
Andrej Klepanec ◽  
Ingrid Olejarova ◽  
Marcela Skrakova
Keyword(s):  
Bone Marrow ◽  
Limb Salvage ◽  
Critical Limb Ischemia ◽  
Bone Marrow Aspirate ◽  
Autologous Bone Marrow ◽  
Limb Ischemia ◽  
Pain Scale ◽  
Cd34 Cells ◽  
Autologous Bone ◽  
Bone Marrow Blood

Abstract Abstract 2999 Introduction: Autologous bone marrow cell application has been proposed as an alternative therapy in patients (pts) with critical limb ischemia (CLI), not eligible for endovascular or surgical revascularization, but the way of their administration is currently unresolved. The aim of our study is to compare intramuscular (i.m.) and intraarterial (i.a.) bone marrow blood (BMB) delivery. Methods: Fifty nine patients (median age 67 years, range 38 – 89; gender M :F = 50 :9) with advanced CLI (Rutherford category 5, 6) not eligible for revascularization underwent analgosedation with profolol and total of 240 ml of BMB from both posterior iliac crests were harvested and stabilized with heparin. Bone marrow aspirate was processed with SmartPreP2 Bone Marrow Aspirate Concentrate System (Harvest, Plymouth, MA) – gradient density centrifugation to provide 40 ml of BMB concentrate (BMBc) within 15–20 minutes. Patients were randomized to treatment with 40 ml of BMBc either using local i.m. or i.a. infusion. Primary end points were limb salvage and wound healing. Secondary end points included changes in transcutaneous oxygen pressure (tcpO2), quality of life questionnaire (EQ 5D), ankle-brachial index (ABI), and pain scale (0–10 scale). Patients with limb salvage and wound healing were considered as responders to BMBc therapy. Results: Fifty nine collected BMB contained median mononucleated cell number 35, 8 × 109/l (range 12, 5 – 79, 8) and CD34+ cells 237, 25 × 106/l (range 57, 2 – 694, 3). Processing of BMB reduced to volume from 240 ml to 40 ml (e.g. 6x) and increased concentration of mononucleated cells and CD34+ cells (2, 9x). According to the randomization BMBc was administered i.m. (24 patients) into the ischemic limb or by means of i.a. infusion (800ml/hour) through the catheter positioned into the popliteal artery (25 patients). Since procedure 41 patients could reach 180 days follow up, 4 patients died from unrelated reason to study and 37 patients were evaluable for response. Twenty seven of 37 had limb salvage (73%). There was significant improvement in tcpO2 (15±10 to 29±13mmHg, p<0.001), in pain scale (4.4±2.6 to 0.9±1.4, p<0.001) and EQ 5D (51±15 to 70±13, p<0.001), and significant decrease in Rutherford category of CLI (5.0±0.2 to 4.3±1.6, p<0.01). There were no differences among functional parameters in patients undergoing i.m. versus i.a. delivery. Responders (n=27) vs. nonresponders (n=10) received higher CD34+ cells amounts in the bone marrow concentrate (29±15×10^6 vs 17±12×10^6, p<0.05), but similar number of total nucleated cells (4.3±1.4×10^9 vs 4.1±1.2×10^9, p=0.66). Responders had significantly lower C-reactive protein level (CRP 18±28 vs 100±96 mg/l, p<0.05) and white blood cell counts (8.3±2.1×10^9/l vs 12.3×4.5×10^9/l, p<0.05) at the time of study procedure. Conclusions: Autologous bone marrow blood harvest and administration is safe. There is no difference in i.m. versus i.a. application, both methods of autologous BMB delivery are effective in pts with CLI. Higher CD34+ cell content in BMBc and lower degree of inflammation are associated with good response to BMB application. Funding of project “Transplantation of autologous bone-marrow stem cells in patients with critical limb ischemia” ITMS code 26240220023 is supported by Operational programme Research and Innovation from European Regional Development Fund. Disclosures: No relevant conflicts of interest to declare.

Hydroxyapatite collagen scaffold with autologous bone marrow aspirate for mandibular condylar reconstruction

2017 ◽  
Vol 45 (9) ◽  
pp. 1566-1572 ◽  
Author(s):  
Debraj Howlader ◽  
U. Vignesh ◽  
Dichen P. Bhutia ◽  
Rahul Pandey ◽  
Sumit Kumar ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Aspirate ◽  
Collagen Scaffold ◽  
Autologous Bone Marrow ◽  
Autologous Bone

scholarly journals Cerebral palsy treatment with autologous bone marrow aspirate concentrate challenges for the future

2020 ◽  
Author(s):  
Dusan Milenko Maric ◽  
Mihajlo Radomir ◽  
Zoran Milankov ◽  
Vladimir Papic ◽  
Danilo Vojvodic ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cerebral Palsy ◽  
Bone Marrow Aspirate ◽  
Muscle Tone ◽  
Brain Magnetic Resonance Imaging ◽  
Autologous Bone Marrow ◽  
Functional Restoration ◽  
Potential Efficacy ◽  
Developmental Age ◽  
Autologous Bone

Abstract Background Cerebral Palsy (CP) is a heterogeneous group of conditions that results in permanent motor disability. Recent studies have suggested that cellular transplantation may have functional efficacy in the treatment of CP. We conducted a pilot study of the intrathecal transplantation of autologous bone marrow aspirate (BMAC) concentrate in children with CP to assess the safety of the procedure as well as its potential efficacy in motor and cognitive functions. Materials and methods Twenty-four patients with CP received BMAC and were evaluated 12 months. The treatment procedure involves three intrathecal BMAC applications along with neurorehabilitation. We assessed potential efficacy by using Gross motor functional classification system, Ashworth scale, Learning accomplishment profile-diagnostic scale, brain magnetic resonance imaging and electroencephalogram. Results The study enrolled 24 CP patients with chronological age from 1-12 years but the current developmental age was from 6 -10 months. After BMAC therapy, immediate improvements were noted within first 7 days, decreased muscle tone, and decreased involuntary limb movements, better head control and decreased salivation. After treatment, 83% patients developed relaxation of the extremities. The cognitive function assessment also revealed significant improvement in 40% patients. The average developmental age of the CP patients after the intervention was 22 months in the field of cognition and, 20 months in the field of locomotor skills, 21 months in the field of speech skills. Conclusion Autologous BMAC transplantation seems to be safe and feasible, and can help reduce the degree of impairment of CP patients and, improve the quality of life. The combination of cell therapy and neurorehabilitation can lead to functional restoration that reduces disability in CP.

Sign in / Sign up

Export Citation Format

Share Document